ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Etiometry Significantly Enhances Platform Capabilities, Extending Insights Beyond the ICU

The addition of high-fidelity waveform data integration provides deeper insights and additional data points available in lower-acuity settings

Etiometry, a leader in clinical decision support software, has announced a significant advancement to its platform with the integration of high-fidelity waveform data to inform and improve existing clinical data interpretation.

By leveraging waveform information alongside existing data streams, including patient monitors, peripheral devices, lab results, and medication data—this enhancement offers deeper insights into patient physiology, enabling clinicians to make even more informed decisions at the point of care. Using this robust data stream, Etiometry’s proprietary FDA-cleared algorithms can now generate novel clinical insights beyond the ICU—extending into lower-acuity settings where waveform data serves as the primary source of patient information.

“This new capability marks a pivotal step in expanding the reach of the Etiometry Platform beyond intensive care, supporting clinical surveillance in lower-acuity settings and across transitions of care within the hospital,” said Etiometry President and CEO Shane Cooke. “With these enhancements, Etiometry continues to advance its mission of improving patient outcomes by delivering scalable, data-driven insights throughout the entire continuum of hospital care.”

The enhancements further expand Etiometry's robust quality improvement (QI) application by storing the high-fidelity waveform data, making it available for ongoing research. At an enterprise level, clinicians are now able to utilize the platform to monitor patients in their end-to-end journey as they transition care settings within the hospital and extract meaningful data insights. The Etiometry QI App has supported more than 150 quality improvement initiatives and research projects, demonstrating the platform's role in enhancing healthcare delivery and enabling clinicians to drive better patient outcomes.

About Etiometry

Founded in 2010, Etiometry is a leader in clinical decision-support software designed to help clinicians in intensive care units make data-driven, proactive decisions. By leveraging advanced analytics and AI-powered insights, the company empowers care teams to detect subtle changes in patient conditions, prevent complications, and improve recovery times.

Etiometry has received 10 FDA clearances and is trusted by leading healthcare institutions worldwide, including top-ranked academic medical centers and pediatric hospitals. The company is committed to advancing patient safety, improving clinical efficiency, and lowering the cost of care through smarter data utilization.

To learn more, visit www.etiometry.com.

Etiometry’s proprietary FDA-cleared algorithms can now generate novel clinical insights beyond the ICU—extending into lower-acuity settings where waveform data serves as the primary source of patient information.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.12
+0.94 (0.39%)
AAPL  255.53
-2.68 (-1.04%)
AMD  231.83
+3.91 (1.72%)
BAC  52.97
+0.38 (0.72%)
GOOG  330.34
-2.82 (-0.85%)
META  620.25
-0.55 (-0.09%)
MSFT  459.86
+3.20 (0.70%)
NVDA  186.23
-0.82 (-0.44%)
ORCL  191.09
+1.24 (0.65%)
TSLA  437.50
-1.07 (-0.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.